Mittwoch, 4. August 2021
Navigation öffnen

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis



Oktober 2020

Letztes Update:

Cabozantinib Oral Tablet

Indikation (Clinical Trials):
Carcinoma, Hepatocellular, Liver Cirrhosis, Fibrosis


Erwachsene (18+)

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest



Joerg Trojan, Prof. Dr.
Principal Investigator
Universitätsklinikum Frankfurt Goethe-Universität


(3 von 7)

Universität Leipzig KöR, Medizinische Fakultät Department für Innere Medizin, Neurologie Klinik für Gastroenterologie
GermanyRekrutierend» Google-Maps
Florian van Bömmel, MD
» Ansprechpartner anzeigen
Alle anzeigen


Detailed Description:

The primary objective is to assess the tolerability of a reduced starting dose of 40 mg

cabozantinib once-daily for 4 weeks and subsequent dose escalation to 60 mg cabozantinib

once-daily to be maintained until disease progression or intolerable toxicities. Using the

same study treatment discontinuation criteria as in the pivotal CELESTIAL trial will allow

for comparison of treatment discontinuation rates due to treatment related adverse events

(TRAEs) defined as unresolved intolerable Grade 2 TRAEs or any unresolved Grade 3 TRAEs (see

Section 6).

Patients eligible for this trial are cirrhotic HCC patients treated with sorafenib or

lenvatinib in first line.

Secondary objectives comprise the assessment of overall survival (OS), progression free

survival (PFS) at 10 weeks, objective response rate (ORR), time on treatment, treatment

exposure (dose intensity/dose reductions), toxicity, and quality of life (QLQ-C30).

In addition, tissue samples (optional) will be analyzed for molecular parameters and immune

cell composition to identify biomarkers potentially associated with clinical efficacy (OS,

PFS and ORR).

This is an open label, single-arm, multicenter phase II trial. 40 patients suffering from

advanced stage hepatocellular carcinoma (HCC) with compensated liver cirrhosis in second line

treatment, after first line treatment with sorafenib or lenvatinib, will be enrolled in this


Patients will be recruited from up to 10 sites and patients withdrawn from the trial will not

be replaced.


Inclusion Criteria:

- Fully-informed written consent.

- Males and females ≥ 18 years of age.

*There are no data that indicate special gender distribution. Therefore, patients will

be enrolled in the study gender-independently.

- Patients with HCC who have been previously treated with sorafenib or lenvatinib in

first line.

- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by

histology/cytology or clinically by guideline criteria in cirrhotic patients.

- Disease that is not amenable to curative surgical and/or locoregional therapies, or

progressive disease after surgical and/or locoregional therapies.

- ECOG performance status ≤ 2.

- Resolution of any acute, clinically significant treatment-related toxicity from prior

therapy to Grade 1 prior to study entry, with the exception of alopecia.

- Women of childbearing potential must have a negative serum pregnancy test result

within 14 days prior to initiation of study treatment.

- For women of childbearing potential (WOCBP): agreement to remain abstinent (refrain

from heterosexual intercourse) or use highly effective contraceptive methods from the

time of signing the informed consent through at least 4 months after the last dose of

study drug, or agree to completely abstain from heterosexual intercourse. Male

patients, even if surgically sterilized (i.e. status post-vasectomy) must agree to

practice effective barrier contraception (e.g. condom) and to refrain from sperm

donation during the entire study treatment period and through at least 4 months after

the last dose of study drug or agree to completely abstain from heterosexual


Exclusion Criteria:

- Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment

or within at least 4 months.

- Significant portal hypertension (moderate or severe ascites). Significant

hypertension, defined as blood pressure ≥ 140 mmHg (systolic) or ≥ 90 mmHg (diastolic)

in repeated measurements.

- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

- Liver cirrhosis Child-Pugh B or C.

- Severely impaired kidney function.

- Elevations of AST/ALT > 5 x ULN at baseline.

- History of encephalopathy in past 12 months.

- Significant cardiovascular disease (such as NYHA Class II or greater cardiac disease,

myocardial infarction, or cerebrovascular accident) within 3 months prior to

initiation of study treatment, unstable arrhythmia, or unstable angina.

- Baseline QTcF > 500 ms.

- Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation

of study treatment, or anticipation of need for a major surgical procedure during the


- Severe infection within 4 weeks prior to initiation of study treatment, including, but

not limited to, hospitalization for complications of infection, bacteremia, or severe


- Any other disease, metabolic dysfunction, physical examination finding, or clinical

laboratory finding that contraindicates the use of an investigational drug, may affect

the interpretation of the results, or may render the patient at high risk from

treatment complications.

- Treatment with investigational systemic therapy within 28 days or five times the

elimination half-life of the investigational product, whichever is longer, prior to

initiation of study treatment.

- Prior cabozantinib use.

- Known or suspected hypersensitivity to cabozantinib or any other excipients of the


- Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose


- Is currently participating in or has participated in a study of an investigational

agent or has used an investigational device within 4 weeks prior to the first dose of

study treatment.

- Patient who has been incarcerated or involuntarily institutionalized by court order or

by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

- Patients who are unable to consent because they do not understand the nature,

significance and implications of the clinical trial and therefore cannot form a

rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].


Primary outcome:

1. Treatment discontinuation rate due to treatment-related adverse events (Time Frame - 27 months):
Any unresolved intolerable Grade 2 TRAE or unresolved Grade ≥ 3 TRAE after 60 mg or 40 mg or any intolerable Grade 2 TRAE or Grade ≥ 3 TRAE after 20 mg will count as treatment discontinuation due to AE.

Secondary outcome:

1. Overall survival (Time Frame - 27 months):
Time from the date of enrollment to the date of death from any cause. Subjects who have not died by the date of data cutoff will be right censored at the last known date alive.

2. Progression free survival (PFS) according to RECIST 1.1 (Time Frame - at 10 weeks):
Time from the date of enrollment to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause. Subjects who have died without a reported disease progression will be considered to have progressed on the date of their death. Subjects who did not progress or have died will be right censored on the date of their last evaluable tumor assessment.

3. Objective response rate (ORR) according to RECIST 1.1 (Time Frame - 27 months):
Objective response rate will be assessed according to RECIST 1.1 (refer to Appendix 5). Objective response rate will be defined as the proportion of subjects experiencing a confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1.

4. Time on treatment (Time Frame - 27 months):
Time on treatment defined as the interval from therapy initiation until premature discontinuation.

5. Treatment exposure (Time Frame - 27 months):
Treatment exposure defined as summary of specific dose intensities on treatment (including dose reductions and interruptions).

6. Treatment-related and -unrelated toxicities (AEs, SAEs) according to NCI CTCAE v5.0 (Time Frame - 27 months):
All observed treatment-related and -unrelated toxicities (type, incidence and severity of AEs and SAEs) and side effects will be graded according to NCI CTCAE v5.0 and the degree of association of each with the study treatment assessed and summarized. The treatment related serious adverse events rate (SAE) will be determined.

7. Quality of Life with the EORTC QLQ-C30 patient questionnaire (Time Frame - 27 months):
Patient reported outcome assessed by the validated EORTC patient quality of life questionnaire QLQ-C30. The questionnaire evaluates the patient's health and activities in everyday life. Values reach from 1 (not at all) to 4 (very much). Low values mean a better outcome.

8. Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR) (Time Frame - 27 months):
The TR projects might include the assessment of the following: FFPE tissue for IHC staining; FFPE tissue for nucleic isolation to assess the expression of biomarkers, determination of genetic alterations in HCC (panel sequencing) or to determine the mutational load.

Geprüfte Regime

  • Cabozantinib Oral Tablet (CABOMETYX):
    Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose